Research ExplorerPublicationsYounger patients with chronic myeloid leukemia do well in sp...

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

Standard

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. / Kalmanti, Lida; Saussele, Susanne; Lauseker, Michael; Proetel, Ulrike; Müller, Martin C; Hanfstein, Benjamin; Schreiber, Annette; Fabarius, Alice; Pfirrmann, Markus; Schnittger, Susanne; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F; Spiekermann, Karsten; Krause, Stefan W; Heim, Dominik; Nerl, Christoph; Hossfeld, Dieter K; Kolb, Hans-Jochem; Hochhaus, Andreas; Hasford, Joerg; Hehlmann, Rüdiger; German Chronic Myeloid Leukemia Study Group.

In: ANN HEMATOL, Vol. 93, No. 1, 2014, p. 71-80.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kalmanti, L, Saussele, S, Lauseker, M, Proetel, U, Müller, MC, Hanfstein, B, Schreiber, A, Fabarius, A, Pfirrmann, M, Schnittger, S, Dengler, J, Falge, C, Kanz, L, Neubauer, A, Stegelmann, F, Pfreundschuh, M, Waller, CF, Spiekermann, K, Krause, SW, Heim, D, Nerl, C, Hossfeld, DK, Kolb, H-J, Hochhaus, A, Hasford, J, Hehlmann, R & German Chronic Myeloid Leukemia Study Group 2014, 'Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV', ANN HEMATOL, vol. 93, no. 1, pp. 71-80. https://doi.org/10.1007/s00277-013-1937-4

APA

Kalmanti, L., Saussele, S., Lauseker, M., Proetel, U., Müller, M. C., Hanfstein, B., Schreiber, A., Fabarius, A., Pfirrmann, M., Schnittger, S., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Krause, S. W., ... German Chronic Myeloid Leukemia Study Group (2014). Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. ANN HEMATOL, 93(1), 71-80. https://doi.org/10.1007/s00277-013-1937-4

Vancouver

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. ANN HEMATOL. 2014;93(1):71-80. https://doi.org/10.1007/s00277-013-1937-4

Bibtex

@article{49d8aff2cca843588bf14995e3638b82,
title = "Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV",
abstract = "Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed patients from the randomized CML study IV to investigate disease manifestations and outcome in different age groups. One thousand five hundred twenty-four patients with BCR-ABL-positive chronic phase CML were divided into four age groups: (1) 16-29 years, n = 120; (2) 30-44 years, n = 383; (3) 45-59 years, n = 495; and (4) ≥60 years, n = 526. Group 1 (adolescents and young adults (AYAs)) presented with more aggressive disease features (larger spleen size, more frequent symptoms of organomegaly, higher white blood count, higher percentage of peripheral blasts and lower hemoglobin levels) than the other age groups. In addition, a higher rate of patients with BCR-ABL transcript levels >10 % on the international scale (IS) at 3 months was observed. After a median observation time of 67.5 months, no inferior survival and no differences in cytogenetic and molecular remissions or progression rates were observed. We conclude that AYAs show more aggressive features and poor prognostic indicators possibly indicating differences in disease biology. This, however, does not affect outcome.",
keywords = "Adolescent, Adult, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Cytarabine, Female, Follow-Up Studies, Fusion Proteins, bcr-abl, Humans, Interferon-alpha, Kaplan-Meier Estimate, Karnofsky Performance Status, Leukemia, Myeloid, Chronic-Phase, Male, Middle Aged, Piperazines, Protein Kinase Inhibitors, Pyrimidines, RNA, Messenger, RNA, Neoplasm, Randomized Controlled Trials as Topic, Risk Factors, Splenomegaly, Treatment Outcome, Young Adult",
author = "Lida Kalmanti and Susanne Saussele and Michael Lauseker and Ulrike Proetel and M{\"u}ller, {Martin C} and Benjamin Hanfstein and Annette Schreiber and Alice Fabarius and Markus Pfirrmann and Susanne Schnittger and Jolanta Dengler and Christiane Falge and Lothar Kanz and Andreas Neubauer and Frank Stegelmann and Michael Pfreundschuh and Waller, {Cornelius F} and Karsten Spiekermann and Krause, {Stefan W} and Dominik Heim and Christoph Nerl and Hossfeld, {Dieter K} and Hans-Jochem Kolb and Andreas Hochhaus and Joerg Hasford and R{\"u}diger Hehlmann and {German Chronic Myeloid Leukemia Study Group}",
year = "2014",
doi = "10.1007/s00277-013-1937-4",
language = "English",
volume = "93",
pages = "71--80",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

AU - Kalmanti, Lida

AU - Saussele, Susanne

AU - Lauseker, Michael

AU - Proetel, Ulrike

AU - Müller, Martin C

AU - Hanfstein, Benjamin

AU - Schreiber, Annette

AU - Fabarius, Alice

AU - Pfirrmann, Markus

AU - Schnittger, Susanne

AU - Dengler, Jolanta

AU - Falge, Christiane

AU - Kanz, Lothar

AU - Neubauer, Andreas

AU - Stegelmann, Frank

AU - Pfreundschuh, Michael

AU - Waller, Cornelius F

AU - Spiekermann, Karsten

AU - Krause, Stefan W

AU - Heim, Dominik

AU - Nerl, Christoph

AU - Hossfeld, Dieter K

AU - Kolb, Hans-Jochem

AU - Hochhaus, Andreas

AU - Hasford, Joerg

AU - Hehlmann, Rüdiger

AU - German Chronic Myeloid Leukemia Study Group

PY - 2014

Y1 - 2014

N2 - Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed patients from the randomized CML study IV to investigate disease manifestations and outcome in different age groups. One thousand five hundred twenty-four patients with BCR-ABL-positive chronic phase CML were divided into four age groups: (1) 16-29 years, n = 120; (2) 30-44 years, n = 383; (3) 45-59 years, n = 495; and (4) ≥60 years, n = 526. Group 1 (adolescents and young adults (AYAs)) presented with more aggressive disease features (larger spleen size, more frequent symptoms of organomegaly, higher white blood count, higher percentage of peripheral blasts and lower hemoglobin levels) than the other age groups. In addition, a higher rate of patients with BCR-ABL transcript levels >10 % on the international scale (IS) at 3 months was observed. After a median observation time of 67.5 months, no inferior survival and no differences in cytogenetic and molecular remissions or progression rates were observed. We conclude that AYAs show more aggressive features and poor prognostic indicators possibly indicating differences in disease biology. This, however, does not affect outcome.

AB - Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed patients from the randomized CML study IV to investigate disease manifestations and outcome in different age groups. One thousand five hundred twenty-four patients with BCR-ABL-positive chronic phase CML were divided into four age groups: (1) 16-29 years, n = 120; (2) 30-44 years, n = 383; (3) 45-59 years, n = 495; and (4) ≥60 years, n = 526. Group 1 (adolescents and young adults (AYAs)) presented with more aggressive disease features (larger spleen size, more frequent symptoms of organomegaly, higher white blood count, higher percentage of peripheral blasts and lower hemoglobin levels) than the other age groups. In addition, a higher rate of patients with BCR-ABL transcript levels >10 % on the international scale (IS) at 3 months was observed. After a median observation time of 67.5 months, no inferior survival and no differences in cytogenetic and molecular remissions or progression rates were observed. We conclude that AYAs show more aggressive features and poor prognostic indicators possibly indicating differences in disease biology. This, however, does not affect outcome.

KW - Adolescent

KW - Adult

KW - Age Factors

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Benzamides

KW - Cytarabine

KW - Female

KW - Follow-Up Studies

KW - Fusion Proteins, bcr-abl

KW - Humans

KW - Interferon-alpha

KW - Kaplan-Meier Estimate

KW - Karnofsky Performance Status

KW - Leukemia, Myeloid, Chronic-Phase

KW - Male

KW - Middle Aged

KW - Piperazines

KW - Protein Kinase Inhibitors

KW - Pyrimidines

KW - RNA, Messenger

KW - RNA, Neoplasm

KW - Randomized Controlled Trials as Topic

KW - Risk Factors

KW - Splenomegaly

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1007/s00277-013-1937-4

DO - 10.1007/s00277-013-1937-4

M3 - SCORING: Journal article

C2 - 24162333

VL - 93

SP - 71

EP - 80

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 1

ER -